Clincosm LogoSign in Get a demo

Serum FGF-23 and Vitamin D Deficiency

Sponsor
Istanbul University (Other)
Overall Status
Completed
CT.gov ID
NCT01102751
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

We aimed to determine the effect of vitamin D replacement therapy on serum FGF-23 concentrations in vitamin D deficient women and to compare the FGF-23 concentrations of vitamin D deficient patients with healthy subjects and patients with genetically-determined hypophosphatemic rickets.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Study group was composed of vitamin D deficient females (n =18, mean age 29.1±9.9 yrs), vitamin D sufficient healthy females (control group; n = 19, mean age 28.5±5.2 yrs) and patients with genetically-determined hypophosphatemic rickets (n=13, mean age 26.5±15.1 yrs). Groups were compared for serum FGF-23, 1,25 dihydroxy vitamin D3, calcium, phosphate, bone turnover markers, intact parathyroid hormone and urinary excretion of calcium and phosphate. Vitamin D deficient group was re-evaluated after a standard treatment regimen.

    Study Design

    Study Type:
    Observational
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Effects Of Vitamin D Replacement Therapy on Serum FGF-23 Concentrations in Vitamin D Deficient Women In Short Term

    Arms and Interventions

    Arm Intervention/Treatment
    Vitamin D deficient females

    (n =18, mean age 29.1±9.9 yrs)
    vitamin D sufficient healthy females

    (control group; n = 19, mean age 28.5±5.2 yrs)
    genetically-determined hypophosphatemic rahitis

    (n=13, mean age 26.5±15.1 yrs)

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      9 Years to 44 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      Yes
      Inclusion Criteria:

      • Serum 25OHD Vitamin <30 ng/mL for group 1

      • Serum 25OHD Vitamin >30 ng/mL for control group

      Exclusion Criteria:

      • Receiving medication(s) affecting bone metabolism

      • History of gastrointestinal disease and malabsorption

      • History of renal and liver disease

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism Istanbul Turkey 34390

      Sponsors and Collaborators

      • Istanbul University

      Investigators

      None specified.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT01102751
      Other Study ID Numbers:
      • Istanbul University
      • Research Fund
      First Posted:
      Apr 13, 2010
      Last Update Posted:
      Apr 13, 2010
      Last Verified:
      Aug 1, 2009
      Keywords provided by , ,
      fibroblast growth factor 23
      Osteomalacia
      vitamin D
      Additional relevant MeSH terms:
      Osteomalacia

      Study Results

      No Results Posted as of Apr 13, 2010